SCHEMBL9907470

SCHEMBL9907470

O=C(O)c1ccc2nccc(-c3cccc(F)c3Cl)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.41
CSNK2B P67870 2/20 0.41
GPBAR1 Q8TDU6 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4C Q9H3R0 2/20 0.38
KDM5A P29375 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
SLC22A12 Q96S37 1/20 0.38
CTSA P10619 1/20 0.38
RORC P51449 3/20 0.37
CYP2C9 P11712 1/20 0.37
MAOA P21397 1/20 0.37
BLVRB P30043 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PIM1 P11309 1/20 0.36
CSNK2A1 P68400 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907343 0.87 DOT1L (0.42) CSNK2A2CSNK2BMAPKAPK2ALDH1A1POLB
SCHEMBL9907466 0.86 ALOX15 (0.47) GPBAR1ALDH1A1HPGDL3MBTL1KDM4C
SCHEMBL9907371 0.85 KMO (0.53) CSNK2A2CSNK2BGPBAR1MAPKAPK2ALDH1A1
SCHEMBL9925388 0.85 CSNK2A2 (0.41) CSNK2A2CSNK2BALDH1A1KDM4CKDM5A
SCHEMBL9907344 0.84 HTR5A (0.43) CSNK2A2CSNK2BMAPKAPK2RORCCYP2C9
SCHEMBL9907839 0.84 HTR5A (0.53)
SCHEMBL9907372 0.82 MAPKAPK2 (0.48) CSNK2A2CSNK2BMAPKAPK2POLBKDM5A
SCHEMBL9907352 0.81 KMO (0.51) CSNK2A2CSNK2BMAPKAPK2KDM4CKDM5A
SCHEMBL9907370 0.81 MAPKAPK2 (0.40) CSNK2A2CSNK2BMAPKAPK2ALDH1A1POLB
SCHEMBL9907348 0.81 MAPKAPK2 (0.44) CSNK2A2CSNK2BMAPKAPK2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CSNK2A2 4132/4885CSNK2B 4303/4885GPBAR1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.